Molecular and Clinical Spectrum of Primary Hyperparathyroidism
Endocrine Reviews · 2023
DOI: 10.1210/endrev/bnad009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Reviews, 2023. Verfasst von Smita Jha und 1 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-1752, …. Hauptthemen laut MEDLINE: Hyperparathyroidism, Primary, Parathyroid Neoplasms, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 575 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Recent data suggest an increase in the overall incidence of parathyroid disorders, with primary hyperparathyroidism (PHPT) being the most prevalent parathyroid disorder. PHPT is associated with morbidities (fractures, kidney stones, chronic kidney disease) and increased risk of death. The symptoms of PHPT can be nonspecific, potentially delaying the diagnosis. Approximately 15% of patients with PHPT have an underlying heritable form of PHPT that may be associated with extraparathyroidal manifestations, requiring active surveillance for these manifestations as seen in multiple endocrine neoplasia type 1 and 2A. Genetic testing for heritable forms should be offered to patients with multiglandular disease, recurrent PHPT, young onset PHPT (age ≤40 years), and those with a family history of parathyroid tumors. However, the underlying genetic cause for the majority of patients with heritable forms of PHPT remains unknown. Distinction between sporadic and heritable forms of PHPT is useful in surgical planning for parathyroidectomy and has implications for the family. The genes currently known to be associated with heritable forms of PHPT account for approximately half of sporadic parathyroid tumors. But the genetic cause in approximately half of the sporadic parathyroid tumors remains unknown. Furthermore, there is no systemic therapy for parathyroid carcinoma, a rare but potentially fatal cause of PHPT. Improved understanding of the molecular characteristics of parathyroid tumors will allow us to identify biomarkers for diagnosis and novel targets for therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-1752, USA.
ORCID-Profile: Smita Jha, William F Simonds
Förderung
- Intramural NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Jha, S., & Simonds, W. F. (2023). Molecular and Clinical Spectrum of Primary Hyperparathyroidism. Endocrine Reviews. https://doi.org/10.1210/endrev/bnad009
Vancouver
Jha S, Simonds WF. Molecular and Clinical Spectrum of Primary Hyperparathyroidism. Endocrine Reviews. 2023. doi:10.1210/endrev/bnad009
BibTeX
@article{Jha2023,
author = {Jha, Smita and Simonds, William F},
title = {Molecular and Clinical Spectrum of Primary Hyperparathyroidism},
journal = {Endocrine Reviews},
year = {2023},
doi = {10.1210/endrev/bnad009}
}
EUVIMED